Peptide for cancer control linked to IL13Rα2 overexpression

Center name Тестовый центр
Summary A Spanish Research Public Organization has developed a peptide capable of inhibiting the signaling of Interleukin 13 mediated by interleukin 13 receptor The peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which it is overexpressed: control of metastasis of colon cancer and other tumors (i.e glioblastoma), asthma, atopic dermatitis or fibrosis. Industrial partners are being sought for licence agreement.
Description of the offer Recent studies have identified a pro-metastatic role for human interleukin 13 (IL-13) in colorectal cancer mediated through the interleukin 13 receptor α2 (IL13Rα2). The binding of IL-13 to IL13Rα2 triggers different cellular pathways to promote migration, invasion and survival of the metastatic cells. In addition, IL13Rα2 is overexpressed in a variety of human tumor types such as glioblastoma, renal cell carcinoma, pancreatic, melanoma, head and neck, mesothelioma and ovarian, where it has been proposed as biomarker and potential therapeutic target. There is a need for improved strategies for treating tumors and other diseases where IL13Rα2 is expressed, like glioblastoma and metastatic colorectal cancer. The authors have found a peptide that is capable of inhibiting IL13/IL13Rα2 signaling. They have also developed a fusion protein with the peptide and at least a heterologous polypeptide. Both can be introduced in a nanoparticle or virus-like particle to be included in a pharmaceutical composition to be used in cancer and metastasis control when IL13Rα2 is overexpressed. Besides this composition can be applied to other pathologies related with IL13Rα2 such as asthma, atopic dermatitis or fibrosis. The Spanish research group has a broad experience in developing novel compounds to be tested as potential candidates to treat colon cancer. The Spanish research centre is searching for a company interested in the developement and commerzialization of these novel compounds under a license agreement. The compounds have only been tested at a laboratory scale, therefore some further development might be needed and the Spanish research centre could collaborate with the company in that project.
Advantages and Innovations A new strategy for the treatment of cancer is presented related to IL13 / IL13Rα2 and the derived metastases Peptides and derivative pharmaceutical compositions can be applied to other pathologies of high incidence
Technological Keywords 06001003 Cytology, Cancerology, Oncology
06001012 Medical Research
06001015 Pharmaceutical Products / Drugs
Market Keywords 05005007 Pulmonary medicine
05005014 Oncology
Copyright Patent(s) applied for but not yet granted
Comments Regarding IPR Status Spanish patent application
Type of Partnership Required License Agreement
Type and Role of Partner Sought Industrial partners are being sought to develop and commercialize the compounds through a patent licence agreement.
Date of creation 03.04.2018
Profile type Technology offer
Profile openness to interact N
Profile from EEN Y

Dear foreign Participant of external economic activity

Welcome to Russian consortium of Enterprise Europe Network website!

Этот сайт использует «cookies» и собирает следующие данные в целях улучшения его работы (Yandex Metrika, Google Analytics) : IP-адрес компьютера, страна, дата и время посещения, тип браузера, тип операционной системы, модель мобильного устройства, тип устроиства. Для продолжения работы с сайтом нажмите: «Согласен(на)»